This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The FDA, along with Taiwanese medical institutions, have been evaluating Pfizer’s mRNA COVID-19 vaccine, questioning the CDC’s omission of known severe “adverse events of special interest” (AESIs) which appeared in post-vaccination studies. read more. read more.
Gritstone bio has reported interim results from an ongoing Phase 1 study evaluating the company’s self-amplifying mRNA (samRNA) vaccine as a boost against Covid-19 (CORAL-BOOST). The Phase I CORAL-BOOST dose-escalation trial (NCT05148962) evaluated Gritstone’s samRNA candidate (GRT-R910) in previously vaccinated healthy older adults.
To develop a vaccine and then get as many people vaccinated as quickly as possible. Advanced monitoring and analysis technology has enabled more than 13 billion COVID-19 vaccinations to be distributed worldwide to date. In an ever-changing environment, more robust and scalable communications solutions are required.
Oragenics and Inspirevax have signed a license agreement to develop the former’s lead intranasal vaccine candidate for Covid-19, NT-CoV2-1. As part of the exclusive international agreement, Oragenics agreed to pursue the vaccine development with the new BDX301 intranasal mucosal adjuvant of Inspirevax.
The ways in which we communicate and consume information are constantly transforming. In 2020, the challenges of the COVID-19 pandemic greatly accelerated the pace of this evolution, with wide-reaching effects on many aspects of medical communications. Q1: What are some ways in which data dissemination has evolved in 2020?
This has been a long time coming and there are countless reasons why I believe virtual collaboration and medical education are here to stay, long after there is a vaccine for COVID-19 and physical distancing guidelines have been lifted. Virtual meetings are not necessarily a replacement for in-person events but rather a supplement”.
If there’s one take-home message about working during a pandemic, it is the enormous value that virtual events, webinars and e-learning can bring when face-to-face meetings and presentations are impossible. Rewind to March of 2020, and pharma companies were facing a communication crisis. The crisis that changed everything.
The vast majority of societies were able to transition their planned physical events to virtual formats within remarkably short periods of time, and some delivered impressive attendee experiences. yes, if vaccines are available; 15.8% Figure 1 What doctors say about virtual events . . And the evolution continues.
As a spokesperson for the PM Society commented, “We were very cognisant and respectful of events unfolding beyond the awards, but after much consideration and speaking with attendees, we decided to go ahead and we’re so glad that we did. Apt words at a digital innovation event, indeed. ………………………….
The World Health Organization has backed the safety of the Oxford University/AstraZeneca vaccine ahead of a key announcement from European safety experts later today. Several major European countries including Germany, Italy and France have temporarily suspended use of the vaccine amid fears that it could be linked to blood clots.
As COVID-19 vaccines are hastily deployed in the UK for priority groups, a debate rages over the government’s controversial strategy to delay time between vaccine doses. When the UK announced the approval of the Pfizer-BioNTech and Oxford-AstraZeneca COVID-19 vaccines, it marked an exciting moment for the nation.
As COVID-19 vaccines are hastily deployed in the UK for priority groups, a debate rages over the government’s controversial strategy to delay time between vaccine doses. When the UK announced the approval of the Pfizer-BioNTech and Oxford/AstraZeneca COVID-19 vaccines, it marked an exciting moment for the nation.
The huge rise in the use of telemedicine services during lockdown has brought care directly to patients in their homes, while pharma’s communications with healthcare professionals (HCPs) has experienced a similar push to digital channels. About the interviewees. Joe Holmes – vice president of marketing services.
Vaccines have been an essential part of protecting public health for decades. However, despite the overwhelming evidence for their effectiveness and safety, there has been an increasing trend of vaccine hesitancy in recent years. What is vaccine hesitancy? Are there any long-term risks with vaccines?
Supply chain challenges take many forms in pharma – from capacity issues, to managing excess safety stock, and ensuring accurate supplier communication. This increase in complexity has left the industry wide open to supply chain shocks from events such as the pandemic, regional conflict, trade disputes, and cyber-attacks.
China’s National Medical Products Administration (NMPA) has granted emergency use authorisation (EUA) for CSPC Pharmaceutical Group’s messenger RNA (mRNA) vaccine, SYS6006, to treat Covid-19. With this regulatory approval, CSPC Pharmaceutical is claimed to be the first company to receive approval for providing an mRNA vaccine in the country.
The online event also heard from Pfizer and patient advocate representatives and looked at how the NIHR’s collective approach allows life sciences firms to engage with patients while remaining aligned with ethics guidelines and codes of conduct – providing a UK solution to a global problem.
Giving your community access to these tests will help reduce uncertainty about what may be causing their symptoms. People don’t want to needlessly isolate themselves and miss work and life events. By having tests at home that are affordable and refillable every 30 days, patients can know if they are positive or negative.
To reduce your child’s anxiety, familiarize them with the location, sequence of events, and medical objects they might experience during the visit. If you use a visual story for a general check-up but the appointment is for a vaccination, your child may become distressed when the doctor unexpectedly pulls out a needle.
Using digital means we can streamline communications, facilitate better patient engagement, and ultimately improve retention rates. The development of the COVID-19 vaccines was a great example of how collaboration between regulators, organisations, clinicians and patients was able to bring impactful results in record time.
Impact of global events moving forward Despite government incentives to bring down energy costs, Gupta predicts that API manufacturers will continue to look for alternative sites outside the EU to maintain profit margins. “The The question is whether rising inflation levels and major global events will allow for development and innovation.
of the draft revised Community Code provides a reduction in the basic data exclusivity period for innovative medicinal products from eight to six years, a revision which did not come as a great surprise to many. As an example, Article 81.1 The European Commission has evidently expended significant effort in developing the proposals.
There is a stark difference in favour of the UK biotech ecosystem in terms of expenses compared to the US biotech ecosystem, and specifically the New England region, says Mark Leuchtenberger, CEO of Oxford-based company SpyBiotech, a vaccine developer that plans to study a human cytomegalovirus infection vaccine in H2 2023.
Some ideas include: Priority access to flu shots or vaccination clinics during peak seasons. Invitations to member-only health and wellness events or workshops. These events can serve as opportunities to educate members about your products and services while fostering a sense of community.
He pointed out that the most recently developed MRAs were established between the EMA and the FDA and include inspections for veterinary products, vaccines, and plasma-derived products. He further suggested that appropriate resources should be available on-site to help host the inspection and use of different communication platforms.
Processes are in place to check on the impact on MRAs with the need to communicate with partners and evaluate at national level. He referred to the recent global events relating to poisoning due to ethylene glycol and diethylene glycol contamination. In summary, companies should communicate.
They count pills, call insurance companies, staff the register and the drive-thru, verify insurance coverage, check inventory, and talk to doctor’s offices, all while answering phones, responding to customer questions and complaints, and sometimes even administering vaccines.
That’s according to the speakers at a roundtable session, held as part of the Reuters Events: Pharma 2021 conference last week, where representatives from across the life science sector answered questions on the future of European healthcare. Takeaways for pharma from the COVID-19 pandemic.
Reintroducing the liaison role of International Board members with individual Chapters and Affiliates has given us direct lines of communication to the mutual benefit of the International Board and the local groups. Shortly after that, I spoke for ISPE at an event in Italy.
From cancer prevention to diabetes awareness, these events help bring communities together. National Influenza Vaccination Week: December 6-12. Also, don’t forget to promote these awareness events on your website and at your pharmacy. National Diabetes Month. COPD Awareness Month.
Leveraging In-House Events and Services In-house events and services can differentiate your pharmacy while providing non-PBM revenue opportunities. Health screening days, vaccination clinics, or wellness workshops are examples of services that can be promoted through targeted marketing.
Developments such as mRNA cancer vaccines , pharmacogenomics and personalised medicine are going to be transformative for the sector, Professor Meier says. And he draws a parallel to the Covid-19 pandemic when pharmacists played a central role when carrying out vaccinations, even in countries where this was previously unprecedented.
The ongoing monthly CMO Moves series is outlining the relationship between pharmaceutical and biotech companies, and CMOs using recent news events and clinical trial catalysts. The vaccine ACI-24.060 elicited an anti-Abeta antibody response in the first patient cohort after six weeks, as per the results.
AAV vectors are commonly associated with in-vivo gene therapies; AdV vectors show promise for vaccine applications including oncolytic virotherapy; and LV vectors are commonly associated with such ex-vivo approaches as CAR-T cell therapy. You may unsubscribe from these ISPE communications at any time. Leave this field blank.
Manufacturing delays and capacity issues that continue to impact the pharmaceutical supply chain have led to medicine shortages around the globe; an issue that has been exacerbated further by geopolitical events, the energy crisis and rising inflation. What are the top three supply-related challenges facing pharmaceutical manufacturers?
Pfizer: Innovation in Every Pill Pfizer stands as a beacon of pharmaceutical innovation, especially after the global success of its COVID-19 vaccine, Comirnaty. Beyond vaccines, Pfizers portfolio includes blockbuster drugs such as Lipitor and Ibrance.
After finishing his degree here, he undertook his pre-registration in a busy community pharmacy in a deprived area of east London. One of the most valuable lessons he learnt from this experience was the importance of communication. ‘As million residents of Hong Kong. But that was not all.
Read on for key stories from this year’s Frontiers Health conference in Italy, unlocking the promise of patient support programmes in oncology, supercharging communications with modular content, and much more. Nicole Raleigh rounds up key highlights from the event. Case study: Syneos Health and VBI Vaccines.
In the event of any sign of bleeding, seek immediate medical advice. The Advisory Committee on Immunization Practices (ACIP) states that this dose or duration-equivalent steroid use is sufficient to suppress the immune system, such that the administration of live vaccines increases the risk of vaccine-associated infection.
FDA did, however, try to identify safety issues through the medical literature and (after 2007 when mandatory safety reporting for OTC human drug products marketed without an approved application became effective) through the adverse event reporting system. billion in damages were brought between 1980 and 1986.
Here, we provide some insights on 3 key topics based on panel discussions with industry leaders at this year’s event. #1. Regarding OWS’s support for vaccine development, Dr Slaoui noted that 5 of the 6 vaccines selected (from a total of 94 programs) are currently in phase 3 development or approved.
Just 13% of people completely trust the pharma companies they interact with, 68% say the interactions feel transactional, and only a third agree that organisations know their communication preferences. Communication and transparency. Hughes said: “Patient services is a very scripted part of the business. About the author.
One in 11 adults aged over 65 have reported a lack of willingness to receive a COVID-19 vaccine, according to a US-based survey. of participants reported they were very willing to receive a COVID-19 vaccine, 27.8% Further work is also needed to identify why different demographic groups have differing attitudes to the vaccine.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content